Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients

Background FKBP51 immunophilin is abundantly expressed by immune cells. Co-inhibitory immune receptor signalling generates the splicing isoform FKBP51s. Tregs stained by FKBP51s are increased in melanoma patients and their counts are associated with anti-CTLA-4 response. An expansion of FKBP51s + PD-L1 + monocytes was measured in a group of non-responding patients to anti-CTLA-4. The aim of this work was to confirm the predictive value of response of FKBP51s + Tregs in a cohort of patients undergoing anti-PD1 treatment and shed light on a monocyte subset co-expressing PD-L1/FKBP51s. Methods Co-cultures of organoids and autologous lymphocytes were used to confirm that tumour T-cell interaction can induce FKBP51s. PBMC immunophenotype and flow cytometry served to assess and monitor FKBP51s + Treg and FKBP51s + PD-L1 + monocytes in 22 advanced melanoma patients treated with anti-PD1. Silencing and overexpression of FKBP51s in human macrophages served to address the protein role in the tolerant macrophages’ behaviour. Results FKBP51s + Tregs count was increased in responders and had a prognostic value. Non-responders showed an early increase in FKBP51s + PD-L1 + monocytes during anti-PD1 treatment. Manipulation of FKBP51s modulated the macrophage–phenotype, with forced protein expression promoting aspects associated with tolerance. Conclusions FKBP51s may guide in the selection and monitoring of melanoma patient candidates to immune-checkpoint-targeted therapy. Manipulation of FKBP51s may overcome resistance.

• Publication year

  2020

• Venue

  British Journal of Cancer

• Publication date

  2020-04-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41416-020-0840-8PMID 32317723PMCID 7283486
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients

  2020cited by this paper
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

  2019cited by this paper
• Turning the Tide Against Regulatory T Cells

  2019cited by this paper
• Triggering MSR1 promotes JNK‐mediated inflammation in IL‐4‐activated macrophages

  2018cited by this paper
• High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

  2018cited by this paper
• A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma

  2017cited by this paper
• Predictors of responses to immune checkpoint blockade in advanced melanoma

  2017cited by this paper
• Resistance to PD1/PDL1 checkpoint inhibition.

  2017cited by this paper
• Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression—A Case Report from the IMMO-GLIO-01 Trial

  2017cited by this paper
• iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

  2017cited by this paper
• FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy

  2017cited by this paper
• Tumour-associated macrophages as treatment targets in oncology

  2017cited by this paper
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  2017cited by this paper
• CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

  2017cited by this paper
• Leading Edge Review Primary , Adaptive , and Acquired Resistance to Cancer Immunotherapy

  2017cited by this paper
• Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.

  2016cited by this paper
• Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

  2015cited by this paper
• FKBP51 employs both scaffold and isomerase functions to promote NF-κB activation in melanoma

  2015cited by this paper
• Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients

  2015cited by this paper
• The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity

  2014cited by this paper
• Tumor-associated macrophages: from mechanisms to therapy.

  2014cited by this paper
• mTORC1 couples immune signals and metabolic programming to establish Treg cell function

  2013cited by this paper
• The Emerging Role of Large Immunophilin FK506 Binding Protein 51 in Cancer

  2011cited by this paper
• Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy

  2010cited by this paper
• Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells

  2010cited by this paper
• Structure‐based classification of 45 FK506‐binding proteins

  2008cited by this paper
• Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1

  2006cited by this paper
• A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway.

  2004cited by this paper
• Peroxisome Proliferator-activated Receptor γ Ligands Regulate Myeloperoxidase Expression in Macrophages by an Estrogen-dependent Mechanism Involving the -463GA Promoter Polymorphism*

  2004influential reference
• Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells.

  2004cited by this paper
• A physical and functional map of the human TNF-α/NF-κB signal transduction pathway

  2004cited by this paper
• Regulation of peptide bond cis/trans isomerization by enzyme catalysis and its implication in physiological processes.

  2003cited by this paper
• Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition.

  1997cited by this paper
• FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition

  1995cited by this paper

• Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types

  2026cites this paper
• Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis

  2025cites this paper
• High-Throughput 3D Bioprinted Organoids of Skin Cancer Utilized for Diagnosis and Personalized Therapy

  2025cites this paper
• The potential impact of RNA splicing abnormalities on immune regulation in endometrial cancer

  2025cites this paper
• Bridging the gap between testing and clinics exploring alternative pre-clinical models in melanoma research.

  2024cites this paper
• Patient-derived melanoma models.

  2024cites this paper
• Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies.

  2024cites this paper
• The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma

  2024cites this paper
• Cell of origin alters myeloid-mediated immunosuppression in lung adenocarcinoma

  2024cites this paper
• Tirofiban prevents the effects of SARS-CoV-2 spike protein on macrophage activation and endothelial cell death

  2024cites this paper
• Aberrant mitochondrial DNA synthesis in macrophages exacerbates inflammation and atherosclerosis

  2024cites this paper
• Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy

  2024cites this paper
• In Vitro Three-Dimensional (3D) Models for Melanoma Immunotherapy

  2023cites this paper
• Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors

  2023cites this paper
• Targeting alternative splicing in cancer immunotherapy

  2023cites this paper
• Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation

  2023cites this paper
• Novel immunosuppressive effect of FK506 by upregulation of PD‐L1 via FKBP51 in heart transplantation

  2022cites this paper
• The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

  2021cites this paper
• Focus on organoids: cooperation and interconnection with extracellular vesicles - is this the future of in vitro modeling?

  2021cites this paper
• Combining Magnetic Resonance Imaging with Systemic Monocyte Evaluation for the Implementation of GBM Management

  2021influential citation
• Metabolic reprogramming and immune regulation in viral diseases

  2021cites this paper